雄激素依赖型和独立型前列腺癌的表观遗传调控。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-06-06 DOI:10.1016/bs.acr.2024.05.007
Jagdish Mishra, Subhajit Chakraborty, Piyasa Nandi, Soumen Manna, Tirthankar Baral, Niharika, Ankan Roy, Prahallad Mishra, Samir Kumar Patra
{"title":"雄激素依赖型和独立型前列腺癌的表观遗传调控。","authors":"Jagdish Mishra, Subhajit Chakraborty, Piyasa Nandi, Soumen Manna, Tirthankar Baral, Niharika, Ankan Roy, Prahallad Mishra, Samir Kumar Patra","doi":"10.1016/bs.acr.2024.05.007","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer is one of the most common malignancies among men worldwide. Besides genetic alterations, epigenetic modulations including DNA methylation, histone modifications and miRNA mediated alteration of gene expression are the key driving forces for the prostate tumor development and cancer progression. Aberrant expression and/or the activity of the epigenetic modifiers/enzymes, results in aberrant expression of genes involved in DNA repair, cell cycle regulation, cell adhesion, apoptosis, autophagy, tumor suppression and hormone response and thereby disease progression. Altered epigenome is associated with prostate cancer recurrence, progression, aggressiveness and transition from androgen-dependent to androgen-independent phenotype. These epigenetic modifications are reversible and various compounds/drugs targeting the epigenetic enzymes have been developed that are effective in cancer treatment. This chapter focuses on the epigenetic alterations in prostate cancer initiation and progression, listing different epigenetic biomarkers for diagnosis and prognosis of the disease and their potential as therapeutic targets. This chapter also summarizes different epigenetic drugs approved for prostate cancer therapy and the drugs available for clinical trials.</p>","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Epigenetic regulation of androgen dependent and independent prostate cancer.\",\"authors\":\"Jagdish Mishra, Subhajit Chakraborty, Piyasa Nandi, Soumen Manna, Tirthankar Baral, Niharika, Ankan Roy, Prahallad Mishra, Samir Kumar Patra\",\"doi\":\"10.1016/bs.acr.2024.05.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Prostate cancer is one of the most common malignancies among men worldwide. Besides genetic alterations, epigenetic modulations including DNA methylation, histone modifications and miRNA mediated alteration of gene expression are the key driving forces for the prostate tumor development and cancer progression. Aberrant expression and/or the activity of the epigenetic modifiers/enzymes, results in aberrant expression of genes involved in DNA repair, cell cycle regulation, cell adhesion, apoptosis, autophagy, tumor suppression and hormone response and thereby disease progression. Altered epigenome is associated with prostate cancer recurrence, progression, aggressiveness and transition from androgen-dependent to androgen-independent phenotype. These epigenetic modifications are reversible and various compounds/drugs targeting the epigenetic enzymes have been developed that are effective in cancer treatment. This chapter focuses on the epigenetic alterations in prostate cancer initiation and progression, listing different epigenetic biomarkers for diagnosis and prognosis of the disease and their potential as therapeutic targets. This chapter also summarizes different epigenetic drugs approved for prostate cancer therapy and the drugs available for clinical trials.</p>\",\"PeriodicalId\":94294,\"journal\":{\"name\":\"Advances in cancer research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cancer research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.acr.2024.05.007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.acr.2024.05.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

前列腺癌是全球男性最常见的恶性肿瘤之一。除基因改变外,包括 DNA 甲基化、组蛋白修饰和 miRNA 介导的基因表达改变在内的表观遗传修饰是前列腺肿瘤发生和癌症进展的主要驱动力。表观遗传修饰因子/酶的异常表达和/或活性导致参与 DNA 修复、细胞周期调控、细胞粘附、细胞凋亡、自噬、肿瘤抑制和激素反应的基因异常表达,从而导致疾病进展。表观基因组的改变与前列腺癌的复发、进展、侵袭性以及从依赖雄激素表型向不依赖雄激素表型的转变有关。这些表观遗传修饰是可逆的,目前已开发出多种针对表观遗传酶的化合物/药物,可有效治疗癌症。本章重点介绍前列腺癌发生和发展过程中的表观遗传学改变,列出用于诊断和预后的不同表观遗传学生物标志物及其作为治疗靶点的潜力。本章还总结了已批准用于前列腺癌治疗的不同表观遗传药物以及可用于临床试验的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Epigenetic regulation of androgen dependent and independent prostate cancer.

Prostate cancer is one of the most common malignancies among men worldwide. Besides genetic alterations, epigenetic modulations including DNA methylation, histone modifications and miRNA mediated alteration of gene expression are the key driving forces for the prostate tumor development and cancer progression. Aberrant expression and/or the activity of the epigenetic modifiers/enzymes, results in aberrant expression of genes involved in DNA repair, cell cycle regulation, cell adhesion, apoptosis, autophagy, tumor suppression and hormone response and thereby disease progression. Altered epigenome is associated with prostate cancer recurrence, progression, aggressiveness and transition from androgen-dependent to androgen-independent phenotype. These epigenetic modifications are reversible and various compounds/drugs targeting the epigenetic enzymes have been developed that are effective in cancer treatment. This chapter focuses on the epigenetic alterations in prostate cancer initiation and progression, listing different epigenetic biomarkers for diagnosis and prognosis of the disease and their potential as therapeutic targets. This chapter also summarizes different epigenetic drugs approved for prostate cancer therapy and the drugs available for clinical trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信